Author’s response to reviews

Title: Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

Authors:

Jose De la Torre Hernandez (he1thj@humv.es;chematorre60@gmail.com)

Mario Sadaba (marsad@secardiologia.es)

Miren Telleria (mtelarr@gmail.com)

Federico Gimeno (fgimenodec@secardiologia.es)

Elena Sanchez Lacuesta (sanchez_mele@gva.es)

Juan Bullones (jantonio.bullones.sspa@juntadeandalucia.es)

Javier Pineda (pineda_jav@gva.es)

Victoria Martin Yuste (27700vmy@comb.cat)

Tamara Garcia Camarero (tgcamarero@gmail.com)

Mariano Larman (mariano.larman@gmail.com)

Jose Rumoroso (rumo@secardiologia.es)

Version: 1 Date: 31 Mar 2017

Author’s response to reviews:

Ibrahim Akin (Reviewer 1):

Lenght of dual antiplatelet therapy should be added.

The prescribed time period for dual antiplatelet therapy was 12 months in all patients but no data on compliance was available.

This information was added in page 10, end of 2nd paragraph.

Then, no differences existed in prescription time for DAPT between study subgroups.
Congratulation to this important Topic.

There is a lack of evidence from literature how to deal with this patient population.

Despite the small amount of patients receiving a thrombolysis, there remains controversy how to deal with them receiving a rescue angioplasty.

There is a Need for randomized Trials to address this important issue.

We know from literature that use of bivalirudine is associated with higher stent thrombosis rates.

We appreciate your words. Completely agree with you. Thanks.